Staging evaluation and surveillance for melanoma patients in a fiscally restrictive medical environment: A commentary

Surgical Clinics of North America

Volumn 76, Issue 6, 1996, Pages 1423-1432

  Ross, M I ^a  

^a Box 106   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE;

CANCER STAGING; CANCER SURVIVAL; COST BENEFIT ANALYSIS; HUMAN; LYMPH NODE DISSECTION; MELANOMA; PATIENT MONITORING; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TECHNIQUE;

EID: 0030447608     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(05)70524-7     Document Type: Article

References (43)

1. C. Balch Cutaneous melanoma: Prognosis and treatment results worldwide Semin Surg Oncol 8 1992 400 414
2. C.M. Balch Soong S.-j. A.A. Bartolucci Efficacy of an elected regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger Ann Surg 224 1996 255 266
3. C. Balch Soong S.-j. H. Shaw An analysis of prognostic factors in 8500 patients with cutaneous melanoma C. Balch A. Houghton G. Milton Cutaneous Melanoma, ed 2 1992 JB Lippincott Philadelphia 165 187
4. C.M. Balch The role of elective lymph node dissection in melanoma: Rationale, results and controversies J Clin Oncol 6 1988 163 172
5. C.M. Balch Soong S.-j. T.M. Murad A multifactorial analysis of melanoma: II. Prognostic factors in patients with stage I (localized) melanoma Surgery 86 1979 343 351
6. C.M. Balch Soong S.-j. T.M. Murad A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II) Ann Surg 193 1981 377 388
7. C.M. Balch Soong S.-j. H.M. Shaw C.M. Balch A.N. Houghton G.W. Milton Cutaneous Melanoma 1992 JB Lippincott Philadelphia 40 45
8. Z. Battayani J.J. Grob L. Xerri Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma Arch Dermatol 131 1995 443 447
9. M. Berwick G. Roush W.D. Thompson Evaluating the efficacy of skin self-exam and other surveillance measures in persons at various levels of risk for cutaneous malignant melanoma: An ongoing case-control study Prog Clin Biol Res 293 1989 297 305
10. C. Blessing U. Feine L. Geiger Positron emission tomography and ultrasonography—A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma Arch Dermatol 131 1995 1394 1398
11. P. Brossart U. Keilholz M. Willhauck Hematogenous spread of malignant melanoma cells in different stages of disease J Invest Dermatol 101 1993 887 889
12. P. Brossart Schmier J.-W. S. Krüger A polymerase chain reaction–based semiquantitative assessment of malignant melanoma cells in peripheral blood Cancer Res 55 1995 4065 4068
13. A. Buzaid A.B. Sandler Mani Role of computed tomography in the staging of primary melanoma J Clin Oncol 11 1993 638 643
14. A. Buzaid L. Tinoco D. Jendiroba Prognostic value of size of lymph node metastases in patients with cutaneous melanoma J Clin Oncol 13 1995 2361 2368
15. A.C. Buzaid L. Tinoco M.I. Ross Role of computed tomography in the staging of patients with local-regional metastases of melanoma J Clin Oncol 13 1995 2104 2108
16. A. Calabro S.E. Singletary C. Balch Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases Arch Surg 124 1989 1051 1055
17. D. Coit A. Rogatko M. Brennan Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis Ann Surg 214 1991 627 636
18. Das Gupta T.K. Results of treatment of 269 patients with primary cutaneous melanoma: A five-year prospective study Ann Surg 186 1977 201 209
19. H. Drepper B. Bieb B. Hofherr The prognosis of patients with stage III melanoma Cancer 71 1993 1239 1246
20. B.D. Fornage J.G. Lorigan Sonographic detection and fine-needle aspiration biopsy of nonpalpable recurrent or metastatic melanoma in subcutaneous tissues J Ultrasound Med 8 1989 421 424
21. M.A. Gadd D.G. Coit Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenectomy for melanoma Arch Surg 127 1992 1412 1416
22. J.W. Gamel S.T. George W.E. Stanley H.F. Seigler Skin melanoma—Cured fraction and survival time as functions of thickness, site, histologic type, age, and sex Cancer 72 1993 1219 1223
23. J. Gershenwald W. Thompson P. Mansfield Patterns of failure in melanoma patients after successful lymphatic mapping and negative sentinel node biopsy [abstract] Proc Soc Surg Oncol 1996
24. G.G. Giles B.K. Armstrong R.C. Burton Has mortality for melanoma stopped risking Australia? Analysis of trends between 1931 and 1994 BMJ 312 1996 1121 1125
25. C.S. Grin D.S. Riegel R.J. Friedman Worldwide incidence of malignant melanoma C.M. Balch Cutaneous Melanoma 1992 JB Lippincott Philadelphia
26. S. Kang R.L. Barnhill M.C. Minn A.J. Sober Multiple primary cutaneous melanomas Cancer 70 1992 1911 1916
27. J. Kirkwood M. Strawderman M. Ernstoff Interferon-alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684 J Clin Oncol 14 1996 7 17
28. B.W. Kuvshinoff C. Kurtz D.G. Coit Computed tomography in the evaluation of patients with stage III melanoma [abstract] Proc Soc Surg Oncol March 1996
29. N. Lane R. Lattes J. Malm Clinicopathological correlations in a series of 117 malignant melanomas of the skin of adults Cancer 11 1958 1025 1043
30. R. MacKie J.A. Hunter T.C. Aitchison Cutaneous malignant melanoma, Scotland, 1979–89: The Scottish Melanoma Group Lancet 339 1992 971 975
31. R.M. MacKie P. McHenry D. Hole Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups Lancet 341 1993 1618 1620
32. T.W. McGovern M.S. Litaker Clinical predictors of malignant pigmented lesions: A comparison of the Glasgow Seven-Point Checklist and the American Cancer Society's ABCDs of pigmented lesions J Dermatol Surg Oncol 18 1992 22 26
33. D.L. Morton D.R. Wen J.H. Wong Technical details of intraoperative lymphatic mapping for early stage melanoma Arch Surg 127 1992 392 399
34. D.S. Reintgen C.W. Cruse C. Berman An orderly progression of melanoma nodal metastases Ann Surg 220 1994 759 767
35. D.S. Reintgen A. Einstein The role of research in cost containment Cancer Control: Journal of the Moffitt Cancer Center 2 1995 429 431
36. D.S. Riegel R.J. Friedman A.W. Kopf The incidence of malignant melanoma in the United States: Issues as we approach the 21st century J Am Acad Dermatol 34 1996 839 847
37. M.R. Robert D.R. Wen A.J. Cochran Pathological evaluation of the regional lymph nodes in malignant melanoma Semin Diagn Pathol 10 1993 102 115
38. M. Ross D.S. Reintgen C. Balch Selective lymphadenectomy: Emerging role of lymphatic mapping and sentinel node biopsy in the management of early stage melanoma Semin Surg Oncol 9 1993 219 223
39. C.R. Shumate M.M. Urist W.A. Maddox Melanoma recurrence surveillance: Patient or physician based? Ann Surg 221 1995 566 571
40. M.N. Sirott D.F. Bajorin G.Y.C. Wong Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis Cancer 72 1993 3091 3098
41. C.L. Slingluff Jr R.K. Dodge W.E. Stanley H.F. Seigler The annual risk of melanoma progression—Implications for the concept of cure Cancer 70 1992 1918 1927
42. U. Veronesi N. Cascinelli Narrow excision (1 cm margin): A safe procedure for thin cutaneous melanoma Arch Surg 126 1991 438 441
43. X. Wang R. Heller N. VanVoorhis Detection of submicroscopic metastases with polymerase chain reaction in patients with malignant melanoma Ann Surg 220 1994 768 774